# ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

Study · id `cardio:ct-nct01848639` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01848639](<https://clinicaltrials.gov/study/NCT01848639>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01848639

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 823 participants.

## Technical summary

Registry record NCT01848639. Randomized; triple masking; primary purpose treatment. Start 2013-06 (actual); primary completion 2022-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 823 participants (enrolled count; ClinicalTrials.gov record NCT01848639, source copy `cardio:ctgov-nct01848639-2023-10-10`, retrieved 2026-10-26)
- Started: 2013-06 (actual) (ClinicalTrials.gov record NCT01848639, source copy `cardio:ctgov-nct01848639-2023-10-10`, retrieved 2026-10-26)
- Primary completion: 2022-11 (actual) (ClinicalTrials.gov record NCT01848639, source copy `cardio:ctgov-nct01848639-2023-10-10`, retrieved 2026-10-26)
- Completion: 2022-11 (actual) (ClinicalTrials.gov record NCT01848639, source copy `cardio:ctgov-nct01848639-2023-10-10`, retrieved 2026-10-26)
- Countries: Belgium; France; Monaco (ClinicalTrials.gov record NCT01848639, source copy `cardio:ctgov-nct01848639-2023-10-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01848639-2023-10-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial
- Acronym: ALCHEMIST
- Condition: End Stage Renal Failure on Dialysis
- Intervention (Drug): Spironolactone
- Intervention (Drug): Placebo
- Lead sponsor: University Hospital, Brest
- Lead sponsor class: OTHER
- Collaborator: Central Hospital, Nancy, France
- Collaborator class: OTHER
- Collaborator: Institut National de la Santé Et de la Recherche Médicale, France
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: University Hospital, Brest (`cardio:org-university-hospital-brest`)
- Registry lists this organization as a collaborator: Central Hospital, Nancy, France (`cardio:org-central-hospital-nancy-france`)
- Registry lists this organization as a collaborator: Institut National de la Santé Et de la Recherche Médicale, France (`cardio:org-institut-national-de-la-sante-et-de-la-recherche-medicale-3ba447`)

## Provenance

Content hash: 8416b81a57bba208b9cd7451ee7128f6a2d5de928b42ae8ac4e944016bb22449
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
